最近三个交易日，28日-30日，春立医疗分别获融资买入0.15亿元、0.06亿元、0.12亿元。 融券方面，当日融券卖出0.00万股，净卖出0.00万股。 7月30日，沪深两融数据显示，春立医疗获融资买入额0.12亿元，居两市第1213位，当日融资偿还额0.07 亿元，净买入560.18万元。 本文源自：金融界 作者：智投君 ...

证券之星消息，截至2025年7月30日收盘，春立医疗(688236)报收于22.5元，下跌0.88%，换手率 1.11%，成交量3.19万手，成交额7327.56万元。 7月30日的资金流向数据方面，主力资金净流入157.48万元，占总成交额2.15%，游资资金净流入43.71 万元，占总成交额0.6%，散户资金净流出201.19万元，占总成交额2.75%。 春立医疗2025年一季报显示，公司主营收入2.3亿元，同比上升3.6%；归母净利润5807.11万元，同比上 升5.2%；扣非净利润5269.81万元，同比上升7.81%；负债率17.11%，投资收益321.7万元，财务费 用-416.65万元，毛利率66.69%。春立医疗（688236）主营业务：植入性骨科医疗器械的研发、生产与 销售。 近5日融资融券数据一览见下表： 该股主要指标及行业内排名如下： | 指标 | 春立医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 86.3亿元 | 115.74亿元 | 42 122 | | 净资产 | 28.79亿元 | 39.18亿元 | 52 12 ...

Group 1 - The core viewpoint of the article highlights that Chunzhi Medical's stock price closed at 22.7 yuan, with a PE ratio of 68.10, marking a new low in 301 days, and a total market capitalization of 8.707 billion yuan [1] - The average PE ratio for the medical device industry is 55.28, with a median of 38.06, positioning Chunzhi Medical at the 89th rank within the industry [1] - As of March 31, 2025, Chunzhi Medical has 7,167 shareholders, an increase of 501 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Chunzhi Medical specializes in the research, production, and sales of implantable orthopedic medical devices, including spinal, trauma, joint, sports medicine, bone repair materials, surgical instruments, and PRP preparation kits [1] - The latest quarterly report for Q1 2025 shows that the company achieved a revenue of 230 million yuan, a year-on-year increase of 3.60%, and a net profit of 58.0711 million yuan, reflecting a year-on-year growth of 5.20%, with a gross profit margin of 66.69% [1]

Summary of Key Points from the Conference Call Industry Overview - The medical device sector is experiencing accelerated approval policies, which are beneficial for the industry, driven by innovation, internationalization, and mergers and acquisitions [1][2] - Companies like Xinmai Medical, Nanwei Medical, and Chunli Medical are actively transforming and showing significant growth in international business, contributing to valuation recovery in the sector [1][2] Core Insights and Arguments - The optimization of centralized procurement policies is shifting focus from low prices to supporting innovative medical devices, which is expected to benefit the development and valuation of related companies [2][5] - The orthopedic industry is seeing a shift towards increased domestic production rates and concentration among leading companies, with significant growth potential in overseas markets [3][10] - Specific companies such as Xinmai Medical and Nanwei Medical are experiencing valuation recovery, with projected valuations around 22-25 times for 2025 [4][6] Future Opportunities in the Medical Device Industry - Future opportunities in the medical device industry are primarily in innovation, internationalization, and frequent mergers and acquisitions [5][7] - High-value consumables are expected to benefit from policy support, particularly in areas like aortic stents, digestive interventions, and minimally invasive surgical consumables [7][9] Performance Expectations for 2025 - The medical device sector is expected to show positive growth across various sub-sectors in 2025, with companies like Huatai Medical and Weidian Medical anticipated to see performance turning points [8][9] - Companies such as Union Medical and Mindray are expected to achieve significant growth in the third quarter, driven by improved bidding data and product performance [8][9] Specific Company Recommendations - Recommended companies include Xinmai Medical, Nanwei Medical, and Guichuang Tongqiao, which are expected to perform well due to their growth potential and favorable market conditions [6][20] - In the Hong Kong market, companies like Guichuang Tongqiao and Weikang Medical are highlighted for their strong performance and innovation capabilities [18][19] Notable Trends and Developments - The IVD sector is facing challenges due to previous rounds of centralized procurement, but there is optimism for gradual improvement in performance in the latter half of the year [28][29] - The high-value consumables sector, particularly in electrophysiology, is expected to see significant growth, with companies like Huatai Medical benefiting from product launches and market acceptance [26][27] Conclusion - The medical device industry is poised for recovery and growth, driven by policy support, innovation, and international expansion. Investors are encouraged to focus on companies demonstrating strong growth potential and favorable market dynamics [1][5][20]

Core Viewpoint - Spring Medical (688236) has adjusted its 2024 profit distribution cash dividend total to RMB 18,727,390.80 (including tax), with a cash dividend of RMB 0.049 per share, reflecting a minor change due to share buybacks [2][3][5]. Trading Information Summary - On July 25, Spring Medical's stock closed at RMB 22.4, up 7.49%, with a turnover rate of 1.99%, trading volume of 57,300 shares, and a transaction amount of RMB 128 million [1]. - The fund flow on the same day showed a net outflow of RMB 847.16 million from main funds, accounting for 6.63% of the total transaction amount, while retail investors had a net inflow of RMB 934.27 million, representing 7.31% of the total [2][5]. Company Announcement Summary - Spring Medical announced an adjustment in the total cash dividend for 2024 from RMB 18,752,317.40 (including tax) to RMB 18,727,390.80 (including tax) due to changes in the number of shares participating in the profit distribution [2][5]. - The company will distribute a cash dividend of RMB 0.49 per 10 shares (including tax), with the actual number of shares participating in the distribution being 382,191,649 shares [2][3]. Legal Opinion Summary - A special legal opinion from Beijing Wanshang Tianqin Law Firm confirmed that the differentiated dividend distribution for A-shares complies with relevant laws and regulations, and the impact on the ex-dividend price is minimal, below 1% [4].

Group 1 - The stock price of Chunli Medical (688236) closed at 22.4 yuan on July 25, 2025, up 15.76% from last week's 19.35 yuan, with a peak price of 23.67 yuan during the week, marking a near one-year high [1] - The total market capitalization of Chunli Medical is 8.592 billion yuan, ranking 42nd out of 126 in the medical device sector and 2009th out of 5148 in the A-share market [1] - The company announced adjustments to the 2024 profit distribution cash dividend total, changing it from 18,752,317.40 yuan (tax included) to 18,727,390.80 yuan (tax included) due to changes in the number of shares in the repurchase special securities account [1][3] Group 2 - The annual equity distribution for 2024 will provide a cash dividend of 0.049 yuan per share (tax included), with the record date set for July 31, 2025, and the ex-dividend date and cash dividend payment date on August 1, 2025 [2] - The actual number of shares participating in the distribution is 382,191,649, with a total profit distribution amount of 18,727,390.80 yuan (tax included) [2] - Different tax rates will apply to individual shareholders and securities investment funds based on their holding periods, with QFII shareholders and Hong Kong market investors subject to a 10% withholding tax [2]

Core Viewpoint - The legal opinion issued by Beijing Wan Shang Tian Qin Law Firm confirms that the differentiated dividend distribution plan of Beijing Chunli Zhengda Medical Device Co., Ltd. complies with relevant laws and regulations, ensuring no harm to the interests of the company and its shareholders [4][10]. Group 1: Differentiated Dividend Distribution - The differentiated dividend distribution is based on the company's 2024 profit distribution plan, which proposes a cash dividend of 0.49 RMB per 10 shares, with no stock dividends or capital reserve transfers [6][8]. - The total number of shares participating in the distribution is 382,191,649, which includes 287,051,149 A shares and 95,140,500 H shares, after excluding the repurchased shares [8][9]. - The company has repurchased 1,376,851 A shares, accounting for approximately 0.4774% of the total A shares, which do not participate in the dividend distribution [6][8]. Group 2: Legal Compliance and Verification - The law firm conducted thorough verification of the documents and materials provided by the company, ensuring their authenticity and completeness [2][3]. - The legal opinion is strictly based on Chinese laws and regulations, and does not cover any non-legal professional matters such as accounting or finance [3][4]. - The law firm confirms that the differentiated dividend distribution aligns with the provisions of the Company Law, Securities Law, and relevant regulatory guidelines [4][10]. Group 3: Impact on Stock Price - The differentiated dividend distribution is expected to have a minimal impact on the A-share ex-dividend reference price, with the absolute value of the impact being less than 1% [10]. - The calculated A-share ex-dividend reference price is approximately 18.7212 RMB per share, based on the last closing price and the cash dividend [9][10].

北京市万商天勤律师事务所 关于 北京市春立正达医疗器械股份有限公司 差异化分红事项的 专项法律意见 关于 为出具本专项法律意见，本所律师声明如下事项： 北京市春立正达医疗器械股份有限公司 差异化分红事项的 专项法律意见 致：北京市春立正达医疗器械股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民共和国公司 法》（以下简称"《公司法》"）、《上海证券交易所上市公司自律监管指引第 7 号——回 购股份（2025 年 3 月修订）》（以下简称"《监管指引第 7 号》"）等法律、法规和规范 性文件以及《北京市春立正达医疗器械股份有限公司章程》（以下简称"《公司章程》"） 的规定，北京市万商天勤律师事务所（以下简称"本所"）接受北京市春立正达医疗 器械股份有限公司（以下简称"公司"）的委托，就公司 2024 年度利润分配所涉及的 A 股差异化分红事项（以下简称"本次差异化分红"）出具本专项法律意见。 律师声明 本所律师系根据《公司法》《证券法》《监管指引第 7 号》《律师事务所从事证券 法律业务管理办法》和《律师事务所证券法律业务执业规则（试行）》等法律、法规、 规范性文件以及监管指引的有 ...

北京市春立正达医疗器械股份有限公司 关于调整 2024 年度利润分配现金分红总额的公告 证券代码：688236 证券简称：春立医疗 公告编号：2025-032 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●北京市春立正达医疗器械股份有限公司（以下简称"公司"）2024 年度利润分 配拟派发现金分红总额由人民币 18,752,317.40 元（含税）调整为 18,727,390.80 元（含 税）。 ●调整原因：截至本公告披露日，因公司回购专用证券账户中股份总数发生变动， 实际参与本次利润分配的股份总数调整为 382,191,649 股（其中包括 287,051,149 股 A 股股份及 95,140,500 股 H 股股份）。根据公司 2024 年年度利润分配方案，按照维持 每股分配比例不变的原则，公司相应调整分配总额。 一、 调整前利润分配方案内容 公司于 2025 年 3 月 28 日召开第五届董事会第二十二次会议、第五届监事会第十 四次会议，于 2025 年 6 月 26 日召开 2024 年年度 ...

北京市春立正达医疗器械股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 相关日期 证券代码：688236 证券简称：春立医疗 公告编号：2025-031 每股现金红利0.049元（含税） | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/7/31 | 2025/8/1 | 2025/8/1 | H 股股东的现金分红有关情况详见本公司分别于 2025 年 3 月 28 日、2025 年 5 月 28 日及 2025 年 6 月 27 日在香港联交所网站（www.hkex.com.hk）发布的相关 公告及通函。 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 6 月 26 日的2024年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股 东。 是否涉及差异 ...